Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
0.150
-0.015 (-8.83%)
At close: Nov 20, 2024, 4:00 PM
0.135
-0.014 (-9.68%)
Pre-market: Nov 21, 2024, 5:49 AM EST
Apollomics Employees
Apollomics had 45 employees as of December 31, 2023. The number of employees increased by 2 or 4.65% compared to the previous year.
Employees
45
Change (1Y)
2
Growth (1Y)
4.65%
Revenue / Employee
$46,689
Profits / Employee
-$1,269,178
Market Cap
16.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 45 | 2 | 4.65% |
| Dec 31, 2022 | 43 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Retractable Technologies | 151 |
| ProPhase Labs | 113 |
| Flora Growth | 108 |
| bioAffinity Technologies | 75 |
| Palatin Technologies | 30 |
| MEI Pharma | 28 |
| Cognition Therapeutics | 28 |
| Akari Therapeutics, | 12 |
APLM News
- 2 months ago - Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - GlobeNewsWire
- 3 months ago - Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial - GlobeNewsWire
- 4 months ago - Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 5 months ago - Apollomics Announces Updated Strategic Focus and Leadership Team Changes - GlobeNewsWire
- 7 months ago - Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene - GlobeNewsWire
- 8 months ago - Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 8 months ago - Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript - Seeking Alpha